Anthony B. El-Khoueiry, MD

Articles

First-Line Systemic Treatment for Advanced HCC

March 9th 2022

Anthony B. El-Khoueiry, MD, provides insight on the evolution of care for frontline systemic therapy in advanced HCC and discusses currently approved first-line standard of care options.

Dr. El-Khoueiry Discusses Research on Biomarkers in HCC

August 10th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses research on biomarkers in hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on Immunotherapy Combinations in HCC

July 26th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses immunotherapy combination in hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on Choosing Between Immunotherapy Agents and TKIs in HCC

July 19th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses choosing between immunotherapy agents and TKIs in hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on the Role of Ramucirumab in Advanced HCC

June 20th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.

Dr. El-Khoueiry on Choosing Between Lenvatinib and Sorafenib in HCC

June 12th 2019

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.

Dr. El-Khoueiry on Evolving Role of Immunotherapy in HCC

October 19th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the role that immunotherapy currently plays, and will continue to play, in the treatment landscape of hepatocellular carcinoma (HCC).

Dr. El-Khoueiry on the Rationale for Evaluating Nivolumab in Advanced HCC

September 14th 2016

Anthony B. El-Khoueiry, MD, associate professor of Clinical Medicine, USC Norris Comprehensive Cancer Center, discusses the rationale for evaluating nivolumab in advanced hepatocellular carcinoma (HCC).